Valuation : Mymetics Corporation

Market Cap 439K 377K 355K 324K 606K 41.5M 608K 4.21M 1.63M 21.25M 1.65M 1.61M 67.69M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.03M 58.34M 53.25M 99.6M 6.82B 99.92M 692M 267M 3.49B 271M 265M 11.13B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
5.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%-30.43% 45
-0.38%-2.64%+42.69%+99.03% 67.98B
-2.71%-0.71%+34.08%+81.43% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-1.42%-4.28%+31.24%+13.27% 25.74B
-1.11%+0.90%+23.12%-18.50% 20.09B
+1.15%-14.24%+219.82%+381.14% 17.16B
+0.20%-4.68%-6.41%+560.92% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average +4.16%+0.94%+106,694.63%+161.67% 27.91B
Weighted average by Cap. -0.81%+0.59%+36.97%+141.12%

Financials

2021 2022
Net sales 430K 370K 348K 317K 594K 40.67M 596K 4.12M 1.59M 20.83M 1.61M 1.58M 66.34M 1.03M 884K 832K 759K 1.42M 97.22M 1.42M 9.86M 3.81M 49.79M 3.86M 3.78M 159M
Net income -4.73M -4.07M -3.83M -3.49M -6.53M -447M -6.55M -45.36M -17.53M -229M -17.76M -17.37M -730M -4.8M -4.13M -3.89M -3.55M -6.64M -454M -6.66M -46.08M -17.81M -233M -18.04M -17.65M -741M
Net Debt 67.1M 57.71M 54.27M 49.54M 92.66M 6.35B 92.96M 644M 249M 3.25B 252M 246M 10.35B 71.68M 61.65M 57.98M 52.93M 98.99M 6.78B 99.31M 687M 266M 3.47B 269M 263M 11.06B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!